Close

Anti-SEMA6A DNA-encoded mAb (DMAb), pVAX1 (DMAb-2168-CQ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-SEMA6A DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • SEMA6A
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-2168-CQ CBXS-3646 Mouse IgG1 Sema-6A
DMAb-2169-CQ CBXS-3597 Mouse IgG1 Sema-6A
DMAb-2170-CQ CBXS-5756 Rat IgG2 Mouse recombinant protein of Semaphorin 6A extracellular domain
DMAb-2171-CQ CBXS-5931 Mouse IgG2 Human recombinant Semaphorin 6A EC domain
DMAb-2172-CQ CBXS-0208 Mouse IgG2b
DMAb-2173-CQ CBXS-1045 Rabbit IgG Recombinant Human Semaphorin 6A/SEMA6A protein
DMAb-2174-CQ CBXS-1155 Rabbit IgG
DMAb-2175-CQ CBXS-1680 Mouse IgG2b NS0-derived recombinant human Semaphorin 6A, Gly19-Thr649, Accession # Q9H2E6
DMAb-2176-CQ CBXS-1694 Rat IgG2a Sf 21-derived recombinant mouse Semaphorin 6A, Gly19-Thr649, Accession # O35464
DMAb-2177-CQ CBXS-2553 Mouse IgG2 Recombinant protein corresponding to human Semaphorin 6A EC domain
DMAb-2178-CQ CBXS-2554 Rat IgG2 Recombinant protein corresponding to mouse Semaphorin 6A
DMAb-2179-CQ CBXS-2725 Mouse IgG2a, κ Partial recombinant corresponding to aa21-121 from human SEMA6A (NP_065847) with GST tag
DMAb-2180-CQ CBXS-3511 Mouse IgG2b NS0-derived, recombinant human Semaphorin 6A aa19-649; Q9H2E6 extracellular domain

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-SEMA6A DNA-encoded mAb (DMAb), pVAX1 (DMAb-2168-CQ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.